•HRES 1179 IH 
Whereas small biotechnology firms deserve a comprehensive, 
prompt, direct, and effective review of their products and 
processes by all Federal agencies of jurisdiction; 
Whereas HIV/AIDS, the most virulent strains of tuberculosis, 
Hepatitis C, pandemic diseases, and other life threat-
ening conditions, including cardiovascular conditions, 
stroke, cancer, sickle cell, neurological conditions, gastro-
intestinal, infectious, autoimmune, and mental illness dis-
eases, are an increasing threat to the life, safety, and the 
fiscal balance of State and local health public health or-
ganizations, especially in areas with high proportions of 
underserved and under-resourced populations; 
Whereas over 1,100,000 persons in the United States are liv-
ing with HIV/AIDS, including a large number of racial 
and ethnic minorities; 
Whereas there is a need to encourage therapies and new drug 
development to treat the unmet medical needs of patients 
with debilitating conditions and life-threatening diseases, 
including those in medically underserved communities; 
Whereas new antibiotic and biologic medicines for these infec-
tions and diseases will not only save lives, but provide 
cost savings vitally important to the improvement of the 
Nation’s health and the reduction of health care costs; 
and 
Whereas small business biotechnology firms need Federal as-
sistance to commercialize products related to new and 
promising technologies, including therapeutics for drug 
resistant pathogens, new approaches to antibiotics based 
on defensin mimetics, adenosine-based synthetic blood 
substitutes, allogeneic cellular immune therapy, peptide- 
based and nanoparticle-based therapeutic HIV vaccines, 
VerDate Nov 24 2008 
22:00 Mar 12, 2010
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR1179.IH
HR1179
pwalker on DSK8KYBLC1PROD with BILLS
•HRES 1179 IH 
HIV vaccine adjuvants, immune-based therapies includ-
ing irreversible pepsin fraction, cytokines, and hormones, 
innovative clinical interventions for adverse, debilitating 
drug related events such as peripheral neuropathy, HIV 
antiviral therapies, and processes including lentiviral- 
based gene therapy, antiviral hyperactivation limiting 
therapeutics, 
autologous 
dendritic 
cell 
therapy, 
Pyrimidinedione-based NNRTIs, dual tropic CCR5 an-
tagonists, point-of-care rapid diagnostics, and therapeutic 
nutrition: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) recognizes that the public deserves the 
safest, most effective, and efficient processes in re-
gards to saving the lives of people living in the 
United States with infectious and chronic diseases; 
(2) supports the domestic development and 
commercialization of biotechnology research by firms 
meeting small business size standards and collabora-
tions with university-based biotechnology research 
facilities; 
(3) supports and seeks to encourage the ad-
vancement of United States-based commercialization 
of point of care therapeutics and diagnostics by 
emerging and small business biotechnology firms for 
domestic and global use; 
(4) recognizes the need to coordinate existing 
public funding to help small business biotechnology 
firms whose products may be lost due to domestic 
VerDate Nov 24 2008 
22:00 Mar 12, 2010
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR1179.IH
HR1179
pwalker on DSK8KYBLC1PROD with BILLS
•HRES 1179 IH 
economic conditions, and fund critical paths for 
small biotechnology drug development and for regu-
latory review and commercial approval; 
(5) encourages the development of a formalized, 
national strategic framework to facilitate techno-
logical advancements in improving the commer-
cialization processes for small business biotechnology 
firms; 
(6) wishes to promote and encourage the cre-
ation of incentives for small business biotechnology 
companies that perform basic and applied research 
through the development and commercialization of 
biotechnology products and processes and their dif-
fusion into national and local economies to improve 
the quality of life of people in the United States; 
(7) encourages the development of a com-
prehensive approach to describing disease popu-
lations and the production of comprehensive re-
search programs that are current with evolving bio-
technology and the unmet needs of diverse patient 
populations; and 
(8) encourages the Office of the Secretary of 
the Department of Health and Human Services to 
develop a Federal Biotechnology Coordinating Coun-
cil representative of small business biotechnology 
VerDate Nov 24 2008 
22:00 Mar 12, 2010
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\HR1179.IH
HR1179
pwalker on DSK8KYBLC1PROD with BILLS
•HRES 1179 IH 
companies, research facilities, and Federal agencies 
with a strategic initiative to facilitate development 
and preserve these small business biotechnology 
firms and coordinate resources and funding mecha-
nisms for this purpose. 
Æ 
VerDate Nov 24 2008 
22:00 Mar 12, 2010
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\HR1179.IH
HR1179
pwalker on DSK8KYBLC1PROD with BILLS